Abstract
Phenoxodiol is an experimental anticancer drug under development as a chemosensitizer intended to reverse multidrug resistance mechanisms in ovarian and prostate cancer cells to most standard cytotoxics. The putative molecular target of phenoxodiol is a cell-surface, tumor-specific NADH oxidase, ENOX2 (tNOX), with phenoxodiol having no apparent effect on the constitutive form of this enzyme ENOX1 (CNOX). Using ENOX2 as the target, this study was conducted to explore the temporal relationship between phenoxodiol and paclitaxel or cisplatin in achieving chemosensitization in HeLa cells which are relatively resistant to both paclitaxel and cisplatin. Sequential addition of phenoxodiol and paclitaxel or phenoxodiol and cisplatin showed greater inhibition of HeLa cell ENOX1 activity and growth compared to adding the drugs simultaneously or individually. In parallel, a similar chemosensitizing response of phenoxodiol for cisplatin was observed. ENOX1 was not affected and trans-platinum had no effect. With spent media from phenoxodiol-treated cells sensitivity was enhanced to both paclitaxel and cisplatin if the cells were first pretreated with phenoxodiol. Similar results were obtained with ENOX2-enriched preparations stripped from the surfaces of phenoxodiol-treated cells. In keeping with a speculative prion model, it seems as though the ENOX2 “remembers” the phenoxodiol and “teaches” other ENOX2 molecules to respond to paclitaxel and cisplatin as if phenoxodiol were still present.
Similar content being viewed by others
References
Brown, D. M., Kelly, G. E., & Husband, A. J. (2005). Flavanoid compounds in maintenance of prostate health and prevention and treatment of cancer. Molecular Biotechnology, 30, 253–270. doi:10.1385/MB:30:3:253.
De Luca, T., Morré, D. M., Zhao, H., & Morré, D. J. (2005). NAD+/NADH and/or CoQ/CoQH2 ratios from plasma membrane electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. BioFactors (Oxford, England), 25, 43–60.
Kamsteeg, J., Rutherford, T., Sapi, E., Hanczaruk, B., Shahabi, S., Flick, M., et al. (2003). Phenoxodiol—an isoflavone analog—induces apoptosis in chemoresistant ovarian cancer cells. Oncogene, 22, 2611–2620. doi:10.1038/sj.onc.1206422.
Morré, D. J., Chueh, P.-J., Yagiz, K., Balicki, A., Kim, C., & Morré, D. M. (2007). ECTO-NOX target for the anticancer isoflavene phenoxodiol. Oncology Research, 16, 299–312. doi:10.1159/000102153.
Goss, G., Quinn, M., Rutherford, T., & Kelly, G. A. (2005). A randomized Phase II study of phenoxodiol with platinum or taxane chemotherapy in chemoresistant epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. European Journal of Cancer (Suppl. 3), 261.
Morré, D. J., & Morré, D. M. (2003). Spectroscopic analyses of oscillation in ECTO-NOX-catalyzed oxidation of NADH. Nonlinearity in Biology Toxicology and Medicine, 1, 345–362. doi:10.1080/15401420390249916.
Lyles, M. M., & Gilbert, H. F. (1991). Catalysis of the oxidative folding of ribonuclease A by protein disulfide isomerase dependence of the rate on the composition of the redox buffer. Biochemistry, 3, 613–619. doi:10.1021/bi00217a004.
Morré, D. J., Gomez-Rey, M. L., Schramke, C., Em, O., Lawler, J., Hobeck, J., et al. (1999). Use of dipyridyl-dithio substrates to measure directly the protein disulfide-thiol interchange activity of the auxin stimulated NADH, protein disulfide reductase of soybean plasma membranes. Molecular and Cellular Biochemistry, 200, 7–13. doi:10.1023/A:1006916116297.
Kishi, T., Morré, D. M., & Morré, D. J. (1999). The plasma membrane NADH oxidase of HeLa cells has hydroquinone oxidase activity. Biochimica et Biophysica Acta, 1412, 66–77. doi:10.1016/S0005-2728(99)00049-3.
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mailia, A. K., Gartner, F. H., Provenzano, M. D., et al. (1985). Measurement of protein using bicinchoninic acid. Analytical Biochemistry, 150, 76–85. doi:10.1016/0003-2697(85)90442-7.
Tompa, P., & Friedrich, P. (1998). Prion proteins as memory molecules: A hypothesis. Neuroscience, 86, 1037–1043. doi:10.1016/S0306-4522(98)00148-1.
Morré, D. J., Morré, D. M., Stevenson, J., MacKellar, W., & McClure, D. (1995). HeLa plasma membranes bind the antitumor sulfonylurea LY181984 with high affinity. Biochimica et Biophysica Acta, 1244, 133–140.
Sedlak, D., Morré, D. M., & Morré, D. J. (2001). A drug-unresponsive and protease-resistant CNOX protein from human sera. Archives of Biochemistry and Biophysics, 386, 106–116. doi:10.1006/abbi.2000.2180.
Hostetler, B., Weston, N., Kim, C., Morré, D. M., & Morré, D. J. (2008). Cancer site-specific isoforms of ENOX2 (tNOX), a cancer-specific cell surface oxidase. Clinical Proteomics. doi:10.1007/s12014-008-9016-x.
del Castillo-Olivares, A., Yantiri, F., Chueh, P.-J., Wang, S., Sweeting, M., Sedlak, D., et al. (1998). A drug-responsive and protease-resistant 34 kD NADH oxidase from the surface of HeLa cells. Archives of Biochemistry and Biophysics, 358, 125–140. doi:10.1006/abbi.1998.0823.
Morré, D. J. (1995). NADH oxidase activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl)urea (LY181984) at an external site. Biochimica et Biophysica Acta, 1240, 201–208. doi:10.1016/0005-2736(95)00164-7.
Morré, D. J., Chueh, P.-J., Lawler, J., & Morré, D. M. (1998). The sulfonylurea-inhibited NADH oxidase activity of HeLa cell plasma membranes has properties of a protein disulfide-thiol oxidoreductase with protein disulfide-thiol interchange activity. Journal of Bioenergetics and Biomembranes, 30, 477–487. doi:10.1023/A:1020594214379.
Morré, D. J. (1998). NADH oxidase: A multifunctional ectoprotein of the eukaryotic cell surface. In H. Asard, A. Bérczi, & R. Caubergs (Eds.), Plasma membrane redox systems and their role in biological stress and disease (pp. 121–156). Dordrecht, The Netherlands: Kluwer Academic Publishers.
Morré, D. J., Bridge, A., Wu, L.-Y., & Morré, D. M. (2000). Preferential inhibition by (−)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture. Biochemical Pharmacology, 60, 937–946. doi:10.1016/S0006-2952(00)00426-3.
Morré, D. J., Chueh, P.-J., & Morré, D. M. (1995). Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proceedings of the National Academy of Sciences of the United States of America, 92, 1831–1835. doi:10.1073/pnas.92.6.1831.
Morré, D. J., Kim, C., Paulik, M., Morré, D. M., & Faulk, W. P. (1997). Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin? Journal of Bioenergetics and Biomembranes, 29, 269–280. doi:10.1023/A:1022414228013.
Morré, D. J., Wu, L.-Y., & Morré, D. M. (1995). The antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N’-(chlorophenyl)urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membrane. Biochimica et Biophysica Acta, 1240, 11–17. doi:10.1016/0005-2736(95)00164-7.
Morré, D. J., Sedlak, D., Tang, X., Chueh, P.-J., Geng, T., & Morré, D. M. (2001). Surface NADH oxidase of HeLa cells lacks intrinsic membrane binding motifs. Archives of Biochemistry and Biophysics, 392, 251–256. doi:10.1006/abbi.2001.2436.
Griffith, J. S. (1967). Self-replication and scrapie. Nature, 315, 1043–1044. doi:10.1038/2151043a0.
Prusiner, S. B. (1994). Biology and genetics of prion diseases. Annual Review of Microbiology, 48, 655–686. doi:10.1146/annurev.mi.48.100194.003255.
Robertson, E. D., & Sweatt, J. D. (1998). A biochemical blueprint for long-term memory. Learning & Memory (Cold Spring Harbor, N.Y.), 6, 381–388.
Morré, D. J., Morré, D. M., & Ternes, P. (2003). Auxin-activated NADH oxidase activity of soybean plasma membranes is distinct from the constitutive plasma membrane NADH oxidase and exhibits prion-like properties. In Vitro Cellular & Developmental Biology. Plant, 39, 368–376. doi:10.1079/IVP2003417.
Kelker, M., Kim, C., Chueh, P.-J., Guimont, R., Morré, D. M., & Morré, D. J. (2001). Cancer isoforms of a tumor-associated cell surface NADH oxidase (tNOX) has properties of a prion. Biochemistry, 40, 7351–7354. doi:10.1021/bi010596i.
Morré, D. J., Dick, S., Bosneaga, E., Balicki, A., Wu, L.-Y., McClain, N., et al. (2008). tNOX (ENOX1) target for chemosensitization—low-dose responses in the hormetic concentration range. American Journal of Pharmacology and Toxicology, 3, 16–26.
Acknowledgment
We thank Peggy Runck for manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Morré, D.J., McClain, N., Wu, LY. et al. Phenoxodiol Treatment Alters the Subsequent Response of ENOX2 (tNOX) and Growth of HeLa Cells to Paclitaxel and Cisplatin. Mol Biotechnol 42, 100–109 (2009). https://doi.org/10.1007/s12033-008-9132-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12033-008-9132-x